Published on March 24, 2026
India’s health ministry has raised alarms over the rising popularity and unregulated use of generic GLP-1 weight-loss drugs, particularly after the recent expiry of the patent for Semaglutide. The announcement comes as the market is inundated with inexpensive versions of these medications, some priced as low as $15 a month, igniting concerns over safety and efficacy.
Semaglutide, originally marketed under the brand name Wegovy, has gained significant attention for its effectiveness in promoting weight loss and managing type 2 diabetes. Its patent expiration has paved the way for pharmaceutical companies to produce generic alternatives, leading to an influx of low-cost options that could appeal to consumers seeking quick and affordable solutions to obesity.
However, health officials are warning that these unregulated supplements may carry risks. The lack of stringent oversight means that the quality, dosage, and purity of the generic drugs are not guaranteed, potentially jeopardizing the health of consumers who might not be aware of the differences. The ministry emphasized the need for caution and thorough research considering these medications.
Furthermore, experts highlight that weight-loss drugs are not a one-size-fits-all solution. While some individuals may benefit from such treatments, others might experience adverse effects or may not achieve the desired results. The increasing availability of these generic drugs raises questions about medical advice, as many people may be tempted to self-medicate without consulting healthcare professionals.
In light of these developments, India’s health ministry has urged citizens to approach weight-loss medications with skepticism and to prioritize consultations with qualified healthcare providers. Officials are also exploring potential regulatory measures to ensure that any generic drugs introduced to the market meet safety and efficacy standards.
The rise of these generic weight-loss treatments reflects a growing trend, as individuals worldwide increasingly seek out affordable weight management options. However, the Indian government’s caution serves as a crucial reminder of the responsibilities associated with pharmaceutical consumption and the need for regulatory frameworks to protect public health.